Omeros Corporation

OMER Healthcare Biotechnology

In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.

16.20 2.59 −13.78%
Market cap
$1.4B
P/E
9.5×
Fwd P/E
2.1×
Dividend yield
—
F-score
2/9
Altman Z
−6.82
Beneish M
−0.06
Dividend safety
n/a

Omeros Corporation (OMER) EV/Sales

Alert me on EV/Sales

As of 16 October 2026, Omeros Corporation (OMER) trades at a EV/Sales of 11.8×. Over the past ten years it has ranged from 0.8× (October 2023) to 1,660× (March 2015); the current reading is higher than 56% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2020 12.5× 74.88%
FY2019 7.1× (66.12%)
FY2018 21.1× 48.94%
FY2017 14.2× 33.07%
FY2016 10.6× (76.53%)
FY2015 45.3× —

Quarterly newest first

Period EV/Sales Change
Jun 2026 6.9× (20.70%)
Mar 2026 8.7× (30.57%)
Sep 2021 12.5× (7.54%)
Jun 2021 13.5× (26.93%)
25 more quarters

Against its own ten years

Low 0.8× High 1,660×
Ten-year median 9.4×
Current reading's percentile 61

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on OMER